The Application of Mineralocorticoid Receptor Antagonists on Pulmonary Arterial Hypertension

The Application of Mineralocorticoid Receptor Antagonists on Pulmonary Arterial Hypertension

碩士 === 國立成功大學 === 臨床醫學研究所 === 105

Bibliographic Details
Main Authors:	Xiao-TingSu, 蘇筱婷
Other Authors:	Ping-Yen Liu
Format:	Others
Language:	en_US
Published:	2017
Online Access:	http://ndltd.ncl.edu.tw/handle/t4sj6a

Similar Items

Mineralocorticoid Receptor Antagonists
by: Ilaria Spoletini, et al.
Published: (2019-01-01)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Some observations on the activities of mineralocorticoids and mineralocorticoid antagonists
by: Huston, G. J.
Published: (1979)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension
by: Divya P. Menon, et al.
Published: (2021-06-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
by: Funder JW
Published: (2013-10-01)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
by: Borst Mathias M, et al.
Published: (2009-12-01)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
by: Jason M. Duran, et al.
Published: (2020-04-01)

Mineralocorticoid hypertension
by: Vishal Gupta
Published: (2011-01-01)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
by: M Kathryn Steiner, et al.
Published: (2008-10-01)

ENDOTHELIUM RECEPTOR ANTAGONISTS IN PULMONARY ARTERIAL HYPERTENSION: YESTERDAY, TODAY, AND TOMORROW
by: T. V. Martynuk, et al.
Published: (2009-08-01)

Treatment of Pulmonary Arterial Hypertension: The Role of HO-1 and Endothelin Receptor Antagonist
by: Hsao-Hsun Hsu, et al.
Published: (2009)

The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
by: S N Avdeev
Published: (2016-07-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
by: Anker, S.D, et al.
Published: (2022)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?
by: Eric R. Barros, et al.
Published: (2017-09-01)

Reducing cardiovascular risk in chronic kidney disease : a focus on mineralocorticoid receptor antagonist and arterial stiffness in primary care
by: Ng, Khai Ping
Published: (2016)

Rates of hospitalization associated with the use of aldosterone receptor antagonists in patients with pulmonary arterial hypertension
by: Morgan E. Corkish, et al.
Published: (2019-08-01)

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
by: Szema Anthony M, et al.
Published: (2011-10-01)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
by: Correale M, et al.
Published: (2018-10-01)

The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
by: Rene Baudrand, et al.
Published: (2018-02-01)

Antagonists of mineralocorticoid receptors in the treatment of patients with post-infarced heart failure: the role of eplerenon
by: Vasily V. Kashtalap, et al.
Published: (2019-01-01)

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure
by: I. V. Zhirov, et al.
Published: (2015-12-01)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
by: Jochen Dutzmann, et al.
Published: (2017-01-01)

Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
by: Róbert Gergely, et al.
Published: (2020-10-01)

Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
by: Rosario Rossi, et al.
Published: (2015-03-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
by: Chin EK, et al.
Published: (2015-08-01)

The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
by: Alexandru Steriade, et al.
Published: (2014-06-01)

Cannot write session to /tmp/vufind_sessions/sess_r74i9mb4t0vakukgmbd3a6pqst